Optimization of bioengineered heparin/heparan sulfate production for therapeutic applications.
Heparin has been used clinically as an anti-coagulant for more than 100 y and the major source of this therapeutic is still animal tissues. Contamination issues in some batches of heparin over 10 y ago have highlighted the need to develop alternative methods of production of this essential drug. 1 Bioengineering heparin by expressing serglycin in mammalian cells is a promising approach that was recently reported by the authors. 2 This addendum explores the approaches that the authors are taking to increase the yield of recombinantly expressed serglycin decorated with heparin/heparan sulfate focusing on cell culture and bioreactor conditions and proposes that the cell microenvironment is a key modulator of heparin biosynthesis.
['Lord|Megan S|MS|http://orcid.org/0000-0002-0506-9811', 'Jung|MoonSun|M|', 'Whitelock|John M|JM|http://orcid.org/0000-0003-1835-802X']
D024861:Genetic Enhancement D005947:Glucose D057809:HEK293 Cells D006493:Heparin D006497:Heparitin Sulfate D006801:Humans D011509:Proteoglycans D011994:Recombinant Proteins D033921:Vesicular Transport Proteins
Heparin heparan sulfate serglycin microenvironment mast cells recombinant expression